Accueil   Diary - News   All news Innate Pharma, first phase II trial with IPH2201

Innate Pharma, first phase II trial with IPH2201

Innate Pharma SA, the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charité Comprehensive Cancer Center (CCCC), Berlin, Germany.


IPH2201-201 is an open label Phase II trial testing IPH2201 as a single agent in a pre-operative setting of squamous cell carcinoma of the oral cavity (OCSCC), a tumor type representative of the larger group of squamous cell cancer of the head and neck.
Innate Pharma newsletter

Read the press release